GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biotech company focused on treating autoinflammatory diseases. Its stock price depends on sales of its lead drug, Arcalyst, and its success in expanding its use. The chart shows the risks and opportunities for the company's single product.
Share prices of companies in the market segment - Pharma immune
Kiniksa is a biopharmaceutical company specializing in the treatment of inflammatory diseases. We classify it as part of the immune-pharma sector, and the chart below reflects the general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Kiniksa Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of autoinflammatory and autoimmune diseases. Its focus on this niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Kiniksa compares to it.
Change in the price of a company, segment, and market as a whole per day
KNSA - Daily change in the company's share price Kiniksa Pharmaceuticals
Shares of Kiniksa Pharmaceuticals, which focuses on treating rare inflammatory diseases, are highly volatile. Change_co measures the market's reaction to clinical trial data. This metric, while unspectacular in itself, is a critical element in the formulas on System.GURU.Markets that assess biotech risks.
Daily change in the price of a set of shares in a market segment - Pharma immune
Kiniksa Pharmaceuticals, Ltd. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with KNSA, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Kiniksa is a biopharmaceutical company specializing in drugs for the treatment of autoinflammatory and autoimmune diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Kiniksa's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kiniksa Pharmaceuticals
Kiniksa is a biotech company specializing in rare diseases. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough medicines.
Annual dynamics of market capitalization of the market segment - Pharma immune
Kiniksa Pharmaceuticals, Ltd. is a biotech company focused on developing drugs for the treatment of rare inflammatory diseases. Its success depends on the commercialization of its approved drugs and the results of its R&D. The chart below shows how its focus on this complex and important medical niche influences its performance in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kiniksa Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kiniksa Pharmaceuticals
The value of Kiniksa, a biopharmaceutical company, depends on the success of its drugs. The monthly fluctuations on the chart reflect sales data for its approved drug for a rare inflammatory disease, as well as news about clinical trials of other candidates in its pipeline.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Kiniksa Pharmaceuticals specializes in drugs for the treatment of autoinflammatory and autoimmune diseases. It is a niche player whose success depends on the approval and commercialization of its developments. The biotech sector performance chart will reveal the overall investment climate, which can be used to assess the market's confidence in the potential of Kiniksa's drug portfolio.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kiniksa Pharmaceuticals is a biotech company focused on treating rare autoimmune and inflammatory diseases. Its performance is unaffected by the economic climate. Based on the market trends shown in the chart, Kiniksa shares are driven by news about clinical trials and the commercial success of its approved drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kiniksa Pharmaceuticals
Shares of Kiniksa Pharmaceuticals, which focuses on autoinflammatory diseases, exhibit high volatility. Weekly price movements are driven by news about clinical trials, the commercial success of approved drugs, and regulatory decisions. The chart below illustrates how short-term events in the biotech sector affect the company's valuation.
Weekly dynamics of market capitalization of the market segment - Pharma immune
How unique is Kiniksa Pharmaceuticals' performance in the biotech sector? This chart compares the company's weekly stock price movements with the overall trend. This helps us understand whether its sharp move, driven by news of a rare disease treatment, is a unique event or a reflection of overall investor sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kiniksa Pharmaceuticals specializes in drugs for the treatment of rare autoimmune and inflammatory diseases. This chart compares its weekly performance to the market. It shows how its shares, like those of other biotech companies, are uncorrelated with the market and are driven by news about their developments.
Market capitalization of the company, segment and market as a whole
KNSA - Market capitalization of the company Kiniksa Pharmaceuticals
The Kiniksa Pharmaceuticals market cap chart reflects its strategy for developing drugs for rare inflammatory diseases. The company's market cap depends on the commercial success of its already approved drug, Arcalyst, and the progress of its other developments. The dynamics show how investors value its niche portfolio.
KNSA - Share of the company's market capitalization Kiniksa Pharmaceuticals within the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of autoinflammatory and autoimmune diseases. Its share of its sector market capitalization reflects the value of its rare disease-focused portfolio. The chart shows how the market success of its approved drugs and research progress influence its industry weight.
Market capitalization of the market segment - Pharma immune
The chart illustrates the overall value of biotech companies targeting rare inflammatory diseases. Kiniksa Pharmaceuticals is a prominent player in this niche. The dynamics in the chart reflect how the market values its portfolio of drugs capable of changing the lives of patients with orphan diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart reflects the economic weight of the fight against rare inflammatory diseases. Kiniksa Pharmaceuticals' market capitalization is the market's valuation of its portfolio of specialized drugs. The line shows how a focus on niche yet complex medical problems allows the biotech company to carve out a unique position in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
KNSA - Book value capitalization of the company Kiniksa Pharmaceuticals
The graph below shows the scientific foundation of Kiniksa Pharmaceuticals. Its line reflects the value of intellectual property in its portfolio of drugs for the treatment of rare autoimmune and inflammatory diseases. An upward trend on the graph indicates progress in clinical development, which is the primary tangible embodiment of the company's value.
KNSA - Share of the company's book capitalization Kiniksa Pharmaceuticals within the market segment - Pharma immune
Kiniksa Pharmaceuticals' tangible assets include R&D centers and specialized equipment for developing drugs for rare autoimmune and inflammatory diseases. The chart shows the company's share of this high-tech scientific infrastructure, which is key to the development of breakthrough treatments.
Market segment balance sheet capitalization - Pharma immune
Kiniksa Pharmaceuticals is a commercial biopharmaceutical company. It not only develops but also sells its drugs, which requires investments in logistics and marketing, making it more capital-intensive than an R&D startup. The graph will show whether this model is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Kiniksa Pharmaceuticals' balance sheet is dedicated to the development and commercialization of drugs for the treatment of rare inflammatory diseases. The company's assets represent financial resources that offer hope to patients with orphan diagnoses where therapeutic options are limited.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals focuses on treating rare autoimmune and inflammatory diseases. Its balance sheet is cash, and its market capitalization is the valuation of its approved drug and other candidates in its pipeline. The chart illustrates how the commercial success of a single niche product can generate significant value for a biotech company.
Market to book capitalization ratio in a market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in inflammatory disease treatments. Its valuation is based on its pipeline. The chart shows how the market perceives the potential of its drugs. A high valuation reflects investors' expectations for approval and commercial success.
Market to book capitalization ratio for the market as a whole
Kiniksa Pharmaceuticals is a biotech company focused on treating autoimmune and inflammatory diseases. The chart shows how the market values the company, with a portfolio of both commercialized and developmental drugs, based on a combination of current sales revenue and expectations for future clinical trial success.
Debts of the company, segment and market as a whole
KNSA - Company debts Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals specializes in developing drugs to treat rare autoimmune and inflammatory diseases. The journey from idea to approved drug requires significant investment. This chart shows how the company uses raised capital, including debt, to fund its breakthrough but risky research.
Market segment debts - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in autoimmune and inflammatory diseases. Their strategy is to rapidly develop drugs with proven mechanisms of action. This chart shows common financial indicators for the pharmaceutical sector, which can be used to assess how Kiniksa funds its accelerated clinical development programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals develops drugs to treat autoinflammatory and autoimmune diseases. This is a niche but complex area of biotechnology. This chart shows how the company funds its development pipeline and how much it relies on external capital to conduct clinical trials and bring drugs to market.
Market segment debt to market segment book capitalization - Pharma immune
Kiniksa Pharmaceuticals specializes in treating rare autoimmune and inflammatory diseases. This chart compares the company's debt raised to fund niche but critical research with the overall market capitalization of the entire immune pharmaceutical sector. It illustrates the financial implications of developing drugs for small patient populations.
Debt to book value of all companies in the market
Kiniksa Pharmaceuticals operates in the rare disease niche. This chart compares its research debt to the overall book value of the entire economy. It shows how ambitious the company's scientific ambitions are and how its capital needs compare to the overall health of the stock market, its source of funding.
P/E of the company, segment and market as a whole
P/E - Kiniksa Pharmaceuticals
This chart shows the valuation of Kiniksa Pharmaceuticals, a biotech focused on treating autoinflammatory diseases. For a company with both approved products and new developments, this metric reflects the balance between current sales and investor confidence in the future success of its research pipeline.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which Kiniksa Pharmaceuticals operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
Kiniksa Pharmaceuticals specializes in the development and commercialization of therapeutic drugs for patients with severe autoinflammatory and autoimmune diseases. The company targets niche but critically important markets. This risk appetite chart helps understand how investors value biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals specializes in drugs for the treatment of autoinflammatory and autoimmune diseases. This chart reflects market expectations regarding the commercial success of its current and future products. It demonstrates investor confidence that the company's niche drugs will find their target audience and generate stable revenue.
%20P%2FE%20Kiniksa%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kiniksa-Pharmaceuticals&v=1772632791801 "Chart of the company's future (projected) P/E Kiniksa Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for patients with severe autoinflammatory and autoimmune diseases. This chart illustrates overall market sentiment toward the biotech sector, helping to assess Kiniksa's potential in its complex and important therapeutic niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772632791860 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Kiniksa Pharmaceuticals is a biotechnology company specializing in drugs for the treatment of rare inflammatory diseases. Demand for its products is inelastic. The company's valuation is determined by the commercial success of its existing drugs and progress in developing new ones, rather than by general economic cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772632791882 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of autoinflammatory and autoimmune diseases. Its cash flows are generated from sales of approved drugs and R&D expenses. This chart shows the balance between current profits and investments in expanding the therapeutic portfolio.
Profit of companies in the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of autoinflammatory and autoimmune diseases. This chart shows the profitability of the immunology segment. The company already has a commercial product, which distinguishes it from many biotechs. Its success in sales and research directly impacts the overall profitability of this complex niche.
Overall market profit
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing drugs for autoinflammatory and autoimmune diseases. Its success and value are determined by progress in clinical trials. Against the backdrop of general economic cycles, illustrated by this chart, Kiniksa is working to develop innovative treatments that address specific medical needs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of autoinflammatory and autoimmune diseases. This chart reflects analysts' expectations for future profits, which depend on sales of its currently approved drug and the success of clinical trials of new candidates. It demonstrates market confidence in the company's niche drug portfolio.
%20profit%20of%20the%20company%20Kiniksa%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kiniksa-Pharmaceuticals&v=1772632792035 "Graph of future (projected) profit of the company Kiniksa Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with autoinflammatory and autoimmune diseases. This chart shows revenue projections for the immunology pharmaceutical segment. It reflects expectations for niche drugs treating rare diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772632792051 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Kiniksa Pharmaceuticals specializes in drugs for the treatment of rare autoimmune and inflammatory diseases. Developing such drugs requires significant investment. The overall profit forecast reflected here influences investor willingness to fund the biotech sector. A positive market makes it easier for Kiniksa to raise funds to advance its drugs through clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772632792063 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of autoinflammatory diseases. With its existing products on the market, P/S ratio is becoming an important metric. It reflects how investors assess the commercial launch of its drugs and their potential in niche but highly profitable segments.
P/S market segment - Pharma immune
Kiniksa Pharmaceuticals specializes in developing treatments for autoinflammatory and autoimmune diseases. The company already has an approved product and several candidates in development. The chart shows how the market assesses the commercial potential of their current drug and the future prospects of their pipeline compared to other biotech companies.
P/S of the market as a whole
Kiniksa Pharmaceuticals is a biotech company specializing in drugs for the treatment of autoinflammatory and autoimmune diseases. Revenue depends on the commercial success of its products. This chart illustrates the average revenue estimate, which helps understand the premium the market is willing to pay for revenue from drugs for rare and complex diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals focuses on developing drugs to treat autoinflammatory and autoimmune diseases. Its valuation depends on the success of its lead drug. This chart reflects investor expectations for future sales of its lead product, based on its potential in its niche and potential for expanded indications.
%20P%2FS%20Kiniksa%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kiniksa-Pharmaceuticals&v=1772632792170 "The graph of the company's future (projected) P/S Kiniksa Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of autoinflammatory and autoimmune diseases. This chart shows how the market assesses the future commercial potential of its drug portfolio compared to other immunology companies, reflecting its confidence in its scientific developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772632792178 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Kiniksa Pharmaceuticals specializes in drugs for the treatment of rare autoinflammatory and autoimmune diseases. The company targets niche markets with high unmet needs. This chart shows investor revenue projections, and Kiniksa demonstrates how orphan disease-focused biotechs can achieve commercial success.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772632792200 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of autoinflammatory and autoimmune diseases. This chart shows revenue from sales of its currently approved drug and, potentially, from collaboration fees. Sales growth depends on successful marketing of the drug and its expanded use.
Sales of companies in the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biotech company focused on autoimmune and inflammatory diseases. This chart shows revenue from its lead commercial product, ARCALYST. It allows investors to track sales trends and assess the commercial success of its leading drug in the market.
Overall market sales
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. Like other companies in this sector, its value is driven by drug development success, not economic cycles. This chart is not relevant for assessing Kiniksa's scientific potential or future revenue.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals specializes in drugs for the treatment of rare autoinflammatory and autoimmune diseases. Its revenue forecast depends on sales of its approved drug and the success of clinical trials of other candidates. This chart shows analysts' expectations for the commercial potential of its portfolio in niche but important areas of medicine.
%20sales%20of%20the%20company%20Kiniksa%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kiniksa-Pharmaceuticals&v=1772632792402 "Schedule of future (projected) sales of the company Kiniksa Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma immune
Kiniksa Pharmaceuticals specializes in developing drugs to treat autoinflammatory and autoimmune diseases. This chart shows projected revenue for the entire immunology segment. It allows investors to assess how large and rapidly growing analysts see this market, which is critical for the commercial prospects of Kiniksa's innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772632792411 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of autoimmune and inflammatory diseases. Its success depends on clinical trial results, not economics. However, the overall market environment, reflected in the chart, is critical for attracting the investment needed to fund its expensive R&D programs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772632792490 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing drugs for autoinflammatory and autoimmune diseases. This chart reflects the active clinical development stage. It does not represent revenue, but rather the amount of research investment, the success of which determines the company's future commercial profitability.
Market segment marginality - Pharma immune
Kiniksa Pharmaceuticals specializes in developing drugs for the treatment of autoinflammatory and autoimmune diseases. This chart shows the commercial returns of its niche portfolio. Achieving above-average profitability would indicate the success of its drugs and high demand for them.
Market marginality as a whole
Kiniksa Pharmaceuticals is a commercial biopharmaceutical company specializing in drugs for rare diseases with high unmet need. This overall recurrence margin chart shows the average hospital rate, while Kiniksa operates in a niche market where a successful drug can achieve blockbuster status and generate high margins.
Employees in the company, segment and market as a whole
Number of employees in the company Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in autoimmune and inflammatory diseases. The growth of its team, especially after the approval of its first drug, reflects the creation of a commercial infrastructure. This graph shows the transition from an R&D-focused company to a fully fledged commercial enterprise.
Share of the company's employees Kiniksa Pharmaceuticals within the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for patients with autoinflammatory and autoimmune diseases. This chart highlights its scientific expertise. It reflects the proportion of immunologists and researchers working in this complex field of medicine that Kiniksa brings together.
Number of employees in the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of autoinflammatory and autoimmune diseases. This chart shows employment in the immunology sector. The growing number of scientists in this field indicates a high interest in new treatment mechanisms and a willingness to invest in the breakthrough therapies Kiniksa is developing.
Number of employees in the market as a whole
Kiniksa Pharmaceuticals is a biopharmaceutical company developing drugs for autoinflammatory and autoimmune diseases. The growth of its scientific team is directly linked to progress in research and clinical trials. This exemplifies the creation of high-value jobs in an innovative sector driven by scientific discovery.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals is a commercial biotech company focused on inflammatory disease treatments. Their value is determined by both sales of existing products and the potential for future development. This chart demonstrates the high value of their intellectual property, which allows them to maintain a high valuation even with a sales force.
%20of%20the%20company%20Kiniksa%20Pharmaceuticals%20(KNSA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kiniksa-Pharmaceuticals-KNSA&v=1772632792824 "Chart of market capitalization per employee (in thousands of dollars) of the company Kiniksa Pharmaceuticals (KNSA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Kiniksa is a biotech company with an approved drug (Arcalyst) for rare inflammatory diseases, as well as other R&D projects. This chart shows the industry average. It helps assess how the market values Kiniksa's hybrid model (R&D and sales) per employee.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772632792830 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of autoimmune and autoinflammatory diseases. The company's value is derived from its scientific potential. This chart reflects the high valuation of each employee by investors, as their research has the potential to lead to breakthrough treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772632792846 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals is a biotech company focused on treating autoimmune and inflammatory diseases. The company has an approved drug (Arcalyst). This chart shows how successfully the company is commercializing its niche, expensive drug, and whether its revenues cover the costs of R&D and the staff working on new drugs.
%20Chart%20Kiniksa%20Pharmaceuticals%20(KNSA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kiniksa-Pharmaceuticals-KNSA&v=1772632792860 "Company Profit Per Employee (in thousands of dollars) Chart Kiniksa Pharmaceuticals (KNSA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Kiniksa Pharmaceuticals is a biotech company with an approved drug (Arcalyst) for the treatment of rare autoimmune diseases. This chart shows the benchmark for "Specialty Pharma." In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high (when a blockbuster drug is approved).
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772632792867 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of autoinflammatory and autoimmune diseases. It operates in a niche R&D area in immunology. This chart shows the market-average profit per employee. It helps understand how the immunology-focused biotech sector, where Kiniksa operates, compares to the norm.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772632792906 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on rare diseases. During the clinical trials phase, its revenue per employee is minimal. The graph reflects the investment phase. A successful product launch will lead to explosive growth in this metric, demonstrating the high value of niche, innovative drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kiniksa-Pharmaceuticals-KNSA&v=1772632792916 "Sales chart per company employee Kiniksa Pharmaceuticals (KNSA)")
Sales per employee in the market segment - Pharma immune
Kiniksa Pharmaceuticals is a commercial biotech company focused on rare autoimmune and inflammatory diseases. This chart shows the average revenue per employee in this segment. It allows us to assess how productive Kiniksa's team (both scientific and commercial) is compared to other companies in the orphan disease niche.
Sales per employee for the market as a whole
Kiniksa Pharmaceuticals (KNSA) is a biotech company focused on immunological diseases. The company already has a commercial product (Arcalyst). This chart shows how successfully their small sales team is promoting this highly specialized and expensive drug. A rising indicator indicates successful commercialization.
Short shares by company, segment and market as a whole
Shares shorted by company Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals is a biotech company focused on treating autoimmune and inflammatory diseases. They already have one approved drug. This chart highlights concerns about their commercial success. Those who are bearish on their drug may believe sales will be low or that other developments in the pipeline will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kiniksa-Pharmaceuticals-KNSA&v=1772632792936 "Short Shares Chart for the Company Kiniksa Pharmaceuticals (KNSA)")
Shares shorted by market segment - Pharma immune
Kiniksa Pharmaceuticals is a biotech company specializing in drugs for the treatment of autoinflammatory diseases. This chart highlights the pessimism in the biotech sector. The rise in short positions across the industry reflects investor concerns about the commercial success of already approved drugs or the risk of failure of new candidates in clinical trials.
Shares shorted by the overall market
Kiniksa Pharmaceuticals (KNSA) is a biopharmaceutical company specializing in the treatment of autoimmune and inflammatory diseases. This chart highlights the overall market pessimism. For KNSA, which is in the transition phase from biotech to profitable pharma, the rising fears are a test. Will investors value its current sales or view it as a risky research project?
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals is a biotech company focused on rare autoinflammatory diseases. The stock is volatile. A chart reading above 70 may reflect positive trial data or FDA approval. Oversold territory (<30) is often associated with research setbacks or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kiniksa-Pharmaceuticals-KNSA&v=1772632792961 "RSI 14 indicator chart for the company's stock Kiniksa Pharmaceuticals (KNSA)")
RSI 14 Market Segment - Pharma immune
Kiniksa Pharmaceuticals is a biopharmaceutical company specializing in rare autoinflammatory and autoimmune diseases. The company already has an approved drug, Arcalyst. This chart shows the overall sentiment in the immunology and rare disease biotech sector. It helps assess how investors view this niche and how KNSA compares to it.
RSI 14 for the overall market
Kiniksa Pharmaceuticals (KNSA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KNSA (Kiniksa Pharmaceuticals)
Kiniksa Pharmaceuticals (KNSA) is a biopharmaceutical company focused on developing and commercializing treatments for autoinflammatory and autoimmune diseases. The chart shows the average target price. It reflects analysts' assessments of the commercial success of their drug, Arcalyst, and the potential of the company's other developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KNSA-Kiniksa-Pharmaceuticals&v=1772632792976 "A chart showing analyst consensus forecasts for the expected stock price. KNSA (Kiniksa Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price KNSA (Kiniksa Pharmaceuticals)
Kiniksa is a biotech company focused on developing drugs to treat rare autoinflammatory and cardiovascular diseases. This chart shows the upside and downside potential of the stock among analysts. It measures the gap between the consensus price forecast and the current price, reflecting their confidence in their flagship drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KNSA-Kiniksa-Pharmaceuticals&v=1772632792982 "A chart showing the difference between the consensus forecast and the actual stock price. KNSA (Kiniksa Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Kiniksa Pharma is a biotech company focused on treating rare autoimmune and inflammatory diseases. Its strategy is to target niche markets with high unmet needs. This chart shows analysts' overall expectations for the entire immunology sector. It reflects whether experts believe R&D in this area will be successful.
Analysts' consensus forecast for the overall market share price
Kiniksa Pharmaceuticals (KNSA) is a biotech company focused on inflammatory and autoimmune diseases. They have one approved product (Arcalyst). This chart, reflecting expert expectations, doesn't affect their demand (diseases are non-cyclical). However, it does impact the risk appetite of investors evaluating their R&D pipeline.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kiniksa Pharmaceuticals
Kiniksa is a biotech company focused on treating rare autoimmune and inflammatory diseases. Their success is built on the foundation of their drug, Arcalyst. This chart is an indicator of their commercialization. It likely aggregates the sales growth rate of their flagship drug and the market valuation of their R&D pipeline targeting other orphan diseases.
AKIMA Market Segment Index - Pharma immune
Kiniksa (KNSA) is a commercial biotech focused on rare immune diseases; the company successfully commercialized Arcalyst (for the treatment of pericarditis). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Kiniksa's niche (rare diseases) model differentiate it from the average pharma company?
The AKIM Index for the overall market
Kiniksa is a commercial-stage biotech focused on rare autoimmune and inflammatory diseases. It's a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding companies like Kiniksa.
